News

Enara Bio highlights Dark Antigens® as a novel class of targets for developing targeted immunotherapies against solid tumors

7th November 2022 Enara Bio highlights Dark Antigens® as a novel class of targets for developing targeted immunotherapies against solid tumors Enara Bio’s unique approach identifying Dark Antigen® candidates and cognate T cells in non-small-cell lung cancer and melanoma detailed in two posters to be presented at the 37th Society for Immunotherapy of Cancer Annual Meeting

ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research

2nd November 2022 ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research

All News

Browse our full news archives

Enara Bio and Collaborators Present Progress Towards Developing MR1-targeted T-Cell Therapies at 12th International CD1-MR1 EMBO Meeting 9th May 2022 Enara Bio announces the appointment of T-cell therapy leader  Dr. Sophie Papa as Chief Medical Officer 1st February 2022 Enara Bio announces the appointment of highly experienced biotech executive Dr. Robert Ang to its Board of Directors 28th September 2021 Enara Bio participates in Boehringer Ingelheim’s  “Taking Cancer On” podcast series 21st June 2021 Enara Bio to present progress of research on novel, cancer-specific, MR1-restricted TCRs at upcoming TCR-based Therapies Summit 9th June 2021 Enara Bio adds further cell therapy and TCR expertise to its Senior Research Team 9th March 2021

Publications

Scientific posters highlighting our Dark Antigens as novel immunotherapy targets for solid tumors

Identification and validation of Dark Antigens™ expressed in multiple solid tumors

Poster (SITC 2022) Identification and validation of Dark Antigens™ expressed in multiple solid tumors

Identification of tumor-reactive T cells targeting melanoma Dark Antigens™

Poster (SITC 2022) Identification of tumor-reactive T cells targeting melanoma Dark Antigens™

Our early research discovering immunogenic ERV-derived antigens

POSTER (SITC 2019) Our early research discovering immunogenic ERV-derived antigens

A short selection of the growing scientific literature that inspires us to shine a light on genomic dark matter

Cancer Immunology Research The Immunopeptidome from a Genomic Perspective: Establishing the Noncanonical Landscape of MHC Class I-Associated Peptides Trends in Cell Biology The dark proteome: translation from noncanonical open reading frames Genome Research LTR retroelement expansion of the human cancer transcriptome and immunopeptidome revealed by de novo transcript assembly